product name Torcetrapib
Description: Torcetrapib, also known as CP-529414, is a potent CETP inhibitor with IC50 of 37 nM, elevates HDL-C and reduces nonHDL-C in plasma. Torcetrapib is a drug being developed to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease. Torcetrapib acts by inhibiting CETP, which normally transfers cholesterol from HDL cholesterol to very low density or low density lipoproteins (VLDL or LDL). Inhibition of this process results in higher HDL levels and reduces LDL levels.
References: Endocrinology. 2009 May;150(5):2211-9; Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):490-7.
600.47
Formula
C26H25F9N2O4
CAS No.
262352-17-0
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 120 mg/mL (199.8 mM)
Water: <1 mg/mL
Ethanol: 6 mg/mL (10.0 mM)
Solubility (In vivo)
Synonyms
CP-529414
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19406480
| In Vitro |
In vitro activity: Torcetrapib dose-dependently increases aldosterone release from H295R cells after either 24 or 48 h of treatment with an EC50 of approximately 80 nM, this effect is mediated by calcium channel as calcium channel blockers completely blocks torcetrapib-induced corticoid release and calcium increase. Torcetrapib (1 μM) significantly increases the expression of steroidogenic gene, CYP11B2 and CYP11B1, in H295R cell lines. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Torcetrapib (< 100 mg, daily) changes the plasma distribution of CETP, as the apparent molecular weight of the CETP has shifted to a larger form, by 2 hours after the dose in healthy young subjects. Torcetrapib treatment with 10 mg, 30 mg, 60 mg, and 120 mg daily and 120 mg twice daily results in 16%, 28%, 62%, 73%, and 91% increases in plasma HDL-C, respectively, with no significant changes in TPC in healthy young subjects. Torcetrapib results in an increase of 72.1% in high-density lipoprotein cholesterol and a decrease of 24.9% in low-density lipoprotein cholesterol, in addition to an increase of 5.4 mm Hg in systolic blood pressure, a decrease in serum potassium, and increases in serum sodium, bicarbonate, and aldosterone, in patients at high cardiovascular risk after 12 months treatment. Torcetrapib increases HDL cholesterol levels by 50% and 60% at dose of 60 mg daily and 120 mg daily, respectively, in both healthy and moderately hyperlipidemic subjects. Torcetrapib 60 mg daily increases HDL-mediated net cholesterol efflux from foam cells primarily by increasing HDL concentrations, whereas 120 mg daily torcetrapib increases cholesterol efflux both by increasing HDL concentration and by causing increased efflux at matched HDL concentrations. Torcetrapib (90 mg/kg/day) results in a 70% inhibition of CE transfer in rabbits fed an atherogenic diet. Torcetrapib (90 mg/kg/day) increases mean HDL-C levels by above 3-fold and apoA-I levels by 2.5-fold in plasma in rabbits fed an atherogenic diet. Torcetrapib-treated animal has a multiple-fold increase in HDL-C AUC and a corresponding reduction in aortic lesion area with 60% reduction of aortic free cholesterol (FC) and cholesteryl ester (EC) in rabbits fed an atherogenic diet. Torcetrapib-treated rabbits stimulate free cholesterol efflux to a significantly greater extent than does sera from control rabbits. |
| Animal model | |
| Formulation & Dosage | |
| References | Endocrinology. 2009 May;150(5):2211-9; Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):490-7. |
